<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00226278</url>
  </required_header>
  <id_info>
    <org_study_id>28130</org_study_id>
    <nct_id>NCT00226278</nct_id>
  </id_info>
  <brief_title>Safety Study of ORG 34517 for Major Depression With Psychotic Features</brief_title>
  <official_title>Prospective, Double Blind, Randomized, Placebo-Controlled Dose Finding Study of the Efficacy and Safety of 2 Target Doses of Org 34517 Used as Adjunct&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <brief_summary>
    <textblock>
      Patients suffering from Major Depressive Disorder with Psychotic features who have received&#xD;
      no changes in their medications in the previous two weeks will receive &quot;usual&quot; treatment of&#xD;
      antidepressants, antipsychotics and/or mood stabilizers and adjunct therapy using ORG34517.&#xD;
      The patient will be hospitalized for up to two weeks to monitor their medications and&#xD;
      progress and will return to the site for periodic assessments.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <completion_date type="Actual">November 2005</completion_date>
  <primary_completion_date type="Actual">November 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Major Depressive Disorder</condition>
  <condition>Psychotic Disorders</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ORG 34517</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  provide voluntary written informed consent for trial participation after the scope and&#xD;
             nature of the investigation have been explained to them, and before starting any trial&#xD;
             related activities&#xD;
&#xD;
          -  be able to speak, read, understand, respond to questions and follow instructions in&#xD;
             English&#xD;
&#xD;
          -  have a DSM-IV severe depressive episode with psychotic features, as diagnosed by the&#xD;
             MINI for single or recurrent episodes&#xD;
&#xD;
          -  have a score on PANSS item &quot;Delusions&quot; AND/OR &quot;Hallucinatory behavior&quot; of at least 4&#xD;
             at screening and baseline&#xD;
&#xD;
          -  have a PANSS Positive Scale score of at least 16 at screening and baseline&#xD;
&#xD;
          -  have a total score of at least 18 on teh HAMD 17 item scale at Screening and Baseline&#xD;
&#xD;
          -  be on a stable dose of usual treatment which has to consist of an anti-depressant, an&#xD;
             antipsychotic, a mood stabilizer or any combination of these three drug classes&#xD;
&#xD;
          -  be 18 up to and including 70 years of age at Screening&#xD;
&#xD;
          -  must be willing to be hospitalized for at least 11 days from Screening onwards.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  have any other psychiatric diagnosis except MDD&#xD;
&#xD;
          -  have a lifetime psychiatric diagnosis of Bipolar Disorder I, schizophrenia or&#xD;
             schizoaffective disorders&#xD;
&#xD;
          -  are at significant risk of committing suicide&#xD;
&#xD;
          -  are currently treated with carbamazepine or valproate&#xD;
&#xD;
          -  are currently treated with midazolam&#xD;
&#xD;
          -  have been treated with electroconvulsive therapy in the current episode&#xD;
&#xD;
          -  are currently treated with more than one antidepressant&#xD;
&#xD;
          -  are currently treated with more than one antipsychotic&#xD;
&#xD;
          -  are currently treated with more than one mood stabilizer&#xD;
&#xD;
          -  have usual treatment started or discontinued in the two weeks before randomization&#xD;
&#xD;
          -  have a usual treatment dose change within the week prior to randomization&#xD;
&#xD;
          -  have any clinically unstable or uncontrollable renal, hepatic, respiratory,&#xD;
             haematological, cardiovascular or cerebrovascular disease that would put the patient&#xD;
             at risk of safety or bias assessment efficacy&#xD;
&#xD;
          -  have known hypersensitivity reactions to glucocorticoid antagonists&#xD;
&#xD;
          -  have any clinically significant abnormal laboratory data&#xD;
&#xD;
          -  have any untreated or uncompensated clinically significant endocrine disorder&#xD;
&#xD;
          -  have a diagnosis or alcohol and/or drug dependence&#xD;
&#xD;
          -  have a confirmed positive result on the drug screening test for any illicit drug&#xD;
             except cannabis&#xD;
&#xD;
          -  are using hormone replacement therapy at Screening&#xD;
&#xD;
          -  require concomitant treatment with corticosteroids&#xD;
&#xD;
          -  are subjects diagnosed with Cushing disease&#xD;
&#xD;
          -  are women of childbearing potential without adequate contraception&#xD;
&#xD;
          -  are women with a positive pregnancy test at screening or baseline or are breastfeeding&#xD;
             mothers&#xD;
&#xD;
          -  are male subjects with current diagnosis of prostrate hypertrophia or past history of&#xD;
             symptoms of prostrate hypertrophia.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James H Kocsis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Weill Cornell Medical College/New York Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2008</verification_date>
  <study_first_submitted>September 22, 2005</study_first_submitted>
  <study_first_submitted_qc>September 23, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2005</study_first_posted>
  <last_update_submitted>March 28, 2008</last_update_submitted>
  <last_update_submitted_qc>March 28, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 31, 2008</last_update_posted>
  <responsible_party>
    <name_title>James H. Kocsis, MD</name_title>
    <organization>Weill Cornell Medical College</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

